Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Schirripa

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Biomarker in Colorectal CancerMarta Schirripa, Heinz-Josef Lenz
Critical Reviews in Oncology/Hematology|February 7, 2016
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerYu Sunakawa, Marta Schirripa, Heinz-Josef Lenz
Expert Opinion on Biological Therapy|January 29, 2011
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Marta Schirripa, et al.
Seminars in Oncology|September 29, 2018
Biomarker-driven and molecular targeted therapies for colorectal cancersMarta Schirripa, Stacey A Cohen, Francesca Battaglin, et al.
Nature Reviews. Clinical Oncology|July 29, 2015
First-line chemotherapy for mCRC—a review and evidence-based algorithmChiara Cremolini, Marta Schirripa, Carlotta Antoniotti, et al.
Expert Opinion on Biological Therapy|July 29, 2017
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectivesFrancesca Battaglin, Vincenzo Dadduzio, Francesca Bergamo, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring AgencyFabrizio Nelli, Enzo Maria Ruggeri, Marta Schirripa, et al.
Drug Safety|January 17, 2019
Safety and Tolerability of c-MET Inhibitors in CancerAlberto Puccini, Nagore I Marín-Ramos, Francesca Bergamo, et al.
Expert Review of Anticancer Therapy|October 29, 2015
TAS-102 for the treatment of metastatic colorectal cancerLisa Salvatore, Daniele Rossini, Roberto Moretto, et al.
Expert Review of Anticancer Therapy|January 18, 2018
The role of tumor angiogenesis as a therapeutic target in colorectal cancerFrancesca Battaglin, Alberto Puccini, Rossana Intini, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Biomarker in Colorectal CancerMarta Schirripa, Heinz-Josef Lenz
Critical Reviews in Oncology/Hematology|February 7, 2016
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerYu Sunakawa, Marta Schirripa, Heinz-Josef Lenz
Expert Opinion on Biological Therapy|January 29, 2011
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Marta Schirripa, et al.
Seminars in Oncology|September 29, 2018
Biomarker-driven and molecular targeted therapies for colorectal cancersMarta Schirripa, Stacey A Cohen, Francesca Battaglin, et al.
Nature Reviews. Clinical Oncology|July 29, 2015
First-line chemotherapy for mCRC—a review and evidence-based algorithmChiara Cremolini, Marta Schirripa, Carlotta Antoniotti, et al.
Expert Opinion on Biological Therapy|July 29, 2017
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectivesFrancesca Battaglin, Vincenzo Dadduzio, Francesca Bergamo, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring AgencyFabrizio Nelli, Enzo Maria Ruggeri, Marta Schirripa, et al.
Drug Safety|January 17, 2019
Safety and Tolerability of c-MET Inhibitors in CancerAlberto Puccini, Nagore I Marín-Ramos, Francesca Bergamo, et al.
Expert Review of Anticancer Therapy|October 29, 2015
TAS-102 for the treatment of metastatic colorectal cancerLisa Salvatore, Daniele Rossini, Roberto Moretto, et al.
Expert Review of Anticancer Therapy|January 18, 2018
The role of tumor angiogenesis as a therapeutic target in colorectal cancerFrancesca Battaglin, Alberto Puccini, Rossana Intini, et al.
Pageof 10